By UGA Biopharma…
UGA Biopharma to celebrate COVID-friendly Christmas
UGA Biopharma wishes everybody out there Merry Christmas and a happy new year! Traditionally the UGA family gathers all together to celebrate Christmas. Due to this year’s special circumstances, UGA decided to celebrate Christmas in the time of COVID-19 in a responsible, socially distanced way.
UGA continues to implement the special measures it put in place at the start of the global coronavirus pandemic, as recommended by the German Federal Ministry of Health. These measures include avoiding physical events to reduce external contact points, following a new shiftwork system and home working wherever possible to reduce internal contacts, and observing safe physical distances and rigorous hygiene with face coverings where necessary.
These measures have allowed UGA to carry on ‘business as usual’ and it is now marking the conclusion of a remarkably successful 2020, with finalization of more than six cell line development customer projects, increased uptake of its Ready-to-use Biosimilar cell lines and First CHOice® cell culture media, and online presence at several digital trade shows, like BIO-Europe, BIO USA, CPhI and many more.
“We may celebrate in different ways in these strange times, but the essential meaning of Christmas remains the same. Therefore, we wish you all health and happiness with our heartfelt greeting of ‘Happy New Year’ for 2021,” says UGA.
“The prospect of new vaccines and new therapies give us real hope that together, we may be able to overcome COVID-19 and move to happier times,” UGA concludes.
About UGA Biopharma
UGA Biopharma GmbH is an experienced contract developer of biologics and biosimilars with the capabilities to handle all necessary steps from cell line development and bioprocess development to the development of purification strategies and appropriate analytics.
The company supplies its customers in Germany and abroad from its headquarter in Hennigsdorf, near Berlin. Several clients have used UGA products in clinical trials or in products that have received market authorization.
UGA Biopharma GmbH CRO activities are centered on cell line development for biologics and biosimilars, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies. Typical clients are biopharma manufacturers, research institutions (like universities and research institutes) as well as start-ups and other CROs that need to outsource CLD, upstream, and/or downstream processing.
UGA’s mission is to fulfil customer requests, recognizing industry needs for high titer, high quality and fast delivery timelines, along with robust CHO cell lines. To this end, UGA can deliver cell lines, reaching titers from 4 to 7 g/L, within four months of receiving the originator sequence.
UGA has also developed its proprietary First CHOice® cell culture media and feeds platform to boost the productivity of cell lines. Furthermore, UGA Biopharma GmbH offers ready-to-use biosimilar cell lines, which allow clients interested in biosimilar development fast track access to a highly biosimilar cell line.
Further information at: www.ugabiopharma.com.